Quest Diagnostics Incorporated (DGX) Stock

About Quest Diagnostics Incorporated

Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.

Quest Diagnostics Incorporated is led by CEO James E. Davis, employs 57,000 people, headquartered in Secaucus, US, publicly traded since 1996.

Quest Diagnostics Incorporated (DGX) stock trades at $235.90 with a market capitalization of $26.04B. The stock is valued at a price-to-earnings (P/E) ratio of 21.70, price-to-book of 2.93, price-to-sales of 1.90. Over the past 52 weeks the stock has ranged between $164.65 and $235.90, and currently trades at its 52-week high. It pays a dividend yielding 1.68%.

On profitability, Quest Diagnostics Incorporated generates a return on equity (ROE) of 13.84%, above the typical market average, return on capital employed of 22.00%, an operating margin of 14.53%, a net profit margin of 9.08%.

In its most recent fiscal year, Quest Diagnostics Incorporated reported annual revenue of $11.0B, net profit of $992.0M, revenue has compounded at 3.2% a year over the last five years, profit at -7.1% a year.

The balance sheet shows a debt-to-equity ratio of 0.95, a current ratio of 1.04, total assets of $16.2B, $420.0M in cash and equivalents.

DGX has an average daily trading volume of 932,537 shares, a beta of 0.59 (less volatile than the overall market).

Official website: www.questdiagnostics.com